chronic hepatitis C
We conclude that combination therapy with ursodeoxycholic acid and interferon-alpha 2b was no more effective than interferon monotherapy in inducing a biochemical response in previously untreated patients with chronic hepatitis C. Ursodeoxycholic acid, however, may be useful in prolonging the biochemical response to interferon therapy.
We conclude that combination therapy with ursodeoxycholic acid and <span class="gene" id="9563925-10-67-86">interferon-alpha 2b</span> was no more effective than interferon monotherapy in inducing a biochemical response in previously untreated patients with <span class="disease" id="9563925-10-210-229">chronic hepatitis C</span>. Ursodeoxycholic acid, however, may be useful in prolonging the biochemical response to interferon therapy.